- Ardena has completed the divestment of its drug substance (API) site in Södertälje, Sweden, to Nanologica AB, with the business reverting to the name Syntagon AB.
- Ardena will remain a customer of the site under an ongoing services agreement and has taken a shareholding in Nanologica.
Ardena has completed the divestment of its drug substance (API) facility in Södertälje, Sweden, to Nanologica AB. The business will operate as a wholly owned subsidiary of the Nanologica Group and will revert to its original name, Syntagon AB. The transaction has been completed following the satisfaction of customary closing conditions.
The Södertälje site is an established small molecule API CDMO employing more than 45 people. It supports customer programmes from early development through clinical supply and commercial manufacturing, and has benefited from recent investments in chromatographic purification and falling film distillation capabilities.
As part of the agreement, Ardena has become a shareholder in Nanologica, and Jeremie Trochu, Chief Executive Officer of Ardena, will join Nanologica’s Board of Directors. Ardena will also remain a customer of the Södertälje facility under an ongoing services agreement, ensuring continuity for existing customer programmes.
“This transaction supports Ardena’s strategy to focus investment and growth on specialised capabilities that enable precision medicines and deliver meaningful patient impact across drug product, nanomedicine, drug conjugates, biomarkers and bioanalysis.”
Jeremie Trochu, CEO of Ardena
Following the divestment, Ardena said it will continue to support customers through an integrated CDMO and contract manufacturing approach, enabling efficient progression from early development through to clinical and commercial stages for complex therapies.
